Navigation Links
Provectus Pharmaceuticals, Inc.'s Investor Presentation Now Available for On-demand Viewing at

NEW YORK, May 7, 2012 /PRNewswire/ -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT,, a development-stage oncology and dermatology biopharmaceutical company, today announced that its May 3rd presentation is now available for on-demand viewing.

LINK: > red "register/ watch event now" button

Provectus Pharmaceuticals, Inc's presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Provectus Pharmaceuticals Inc.

Provectus Pharmaceuticals (PVCT) specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.


Since 2010,, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

SOURCE Provectus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
2. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
3. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
4. Avion Pharmaceuticals, LLC Names Michael Sullivan as new VP, Sales and Marketing
5. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
6. Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™
7. Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
8. Gamma Pharmaceuticals, Inc. Announces Key Appointment in Sales and Marketing
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results
11. Tibet Pharmaceuticals, Inc. Announces Intent to Go Private
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 ... today announced that its Chief Executive Officer, ... the Oppenheimer Annual Healthcare Conference in New ... in the conference through a webcast on ... , --> ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing , ... a container patent that allows for easier packing and organizing of items into one ... $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services ... Jordan Industries International, LLC (“JII”). , With support from JII, Integrated Rental is ... to hospitals, surgery centers, clinics, research labs and medical facilities across the United ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in five ... one in three aged 18 to 25 is inked). As tattoos transition to mainstream ... fact, RealSelf , the world’s largest community for learning and sharing information about ...
Breaking Medicine News(10 mins):